Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Mercaptopurine
Drug ID BADD_D01392
Description An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia.
Indications and Usage For remission induction and maintenance therapy of acute lymphatic leukemia.
Marketing Status Prescription
ATC Code L01BB02
DrugBank ID DB01033
KEGG ID D00161
MeSH ID D015122
PubChem ID 667490
TTD Drug ID D09UZO
NDC Product Code 60763-601; 69076-913; 15308-0712; 12780-0299; 62991-2899; 0378-3547; 0054-4581; 38779-1427
Synonyms Mercaptopurine | 6H-Purine-6-thione, 1,7-dihydro- | 6-Mercaptopurine Monohydrate | 6 Mercaptopurine Monohydrate | 6-Thiopurine | 6 Thiopurine | 1,7-Dihydro-6H-purine-6-thione | 6-Mercaptopurine | 6 Mercaptopurine | 6-Thiohypoxanthine | 6 Thiohypoxanthine | Purinethol | Puri-Nethol | Mercaptopurina Wellcome | Leupurin | BW 57-323H | BW 57 323H | BW 57323H | Purimethol | Mecaptopurine Anhydrous
Chemical Information
Molecular Formula C5H4N4S
CAS Registry Number 50-44-2
SMILES C1=NC2=C(N1)C(=S)N=CN2
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Adverse drug reactionNuclear receptor subfamily 4 group A member 3Q92570T9394912709428; 12082103; 15956351; 16604165
ApoptosisNuclear receptor subfamily 4 group A member 3Q92570T9394912709428; 12082103; 15956351; 16604165
ArteriosclerosisNuclear receptor subfamily 4 group A member 3Q92570T9394912709428; 12082103; 15956351; 16604165
Bone marrow toxicityThiopurine S-methyltransferaseP51580Not Available15228171; 9893619; 12525681
InflammationNuclear receptor subfamily 4 group A member 3Q92570T9394912709428; 12082103; 15956351; 16604165
Nervous system disordersNuclear receptor subfamily 4 group A member 3Q92570T9394912709428; 12082103; 15956351; 16604165
Soft tissue neoplasms malignant and unspecifiedNuclear receptor subfamily 4 group A member 3Q92570T9394912709428; 12082103; 15956351; 16604165
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Thrombocytopenia01.08.01.0020.017321%Not Available
Tuberculosis11.04.01.0060.003849%Not Available
Ulcer08.03.06.001--Not Available
Ureteric obstruction20.06.01.0050.005774%Not Available
Urinary tract infection20.08.02.001; 11.01.14.004--
Venoocclusive liver disease24.04.07.002; 09.01.06.0020.003849%
Vitamin B12 decreased13.02.05.0020.003849%Not Available
Vomiting07.01.07.0030.025019%
Weight decreased13.15.01.005--
White blood cell count decreased13.01.06.0120.005774%
Histiocytosis haematophagic10.02.01.042; 01.05.01.0150.011547%Not Available
Cytomegalovirus chorioretinitis11.05.01.006; 06.04.06.0090.003849%Not Available
Nodular regenerative hyperplasia09.01.04.0040.005774%Not Available
Hyperuricosuria20.02.01.019--Not Available
Bone marrow toxicity12.03.01.006; 01.03.03.004--Not Available
Lymphatic disorder01.09.01.003--Not Available
Musculoskeletal discomfort15.03.04.001--Not Available
Transaminases increased13.03.01.0150.003849%Not Available
Ocular icterus09.01.01.007; 06.08.03.009; 01.06.04.0070.003849%Not Available
Hyperinsulinaemia14.06.03.005; 05.06.03.0050.003849%Not Available
Hepatic enzyme increased13.03.01.0190.005774%Not Available
Bacterial infection11.02.01.0050.001004%Not Available
Breast disorder21.05.04.004--Not Available
Feeding disorder19.09.01.003; 14.03.02.0030.003849%Not Available
Malnutrition14.03.02.004--Not Available
Decreased appetite14.03.01.005; 08.01.09.028--
Polyp16.02.02.005; 08.01.06.010--Not Available
Blood disorder01.05.01.004--Not Available
Drug intolerance08.06.01.0130.007698%Not Available
Pulmonary toxicity22.01.02.007; 12.03.01.0130.003849%Not Available
The 5th Page    First    Pre   5 6    Next   Last    Total 6 Pages